International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation.
Palumbo A et al. J Clin Oncol. 2014 Jan 13. [Epub ahead of print].

Initial treatment of transplant-eligible patients in multiple myeloma.
RosiƱol L et al. Expert Rev Hematol. 2014 Jan 7. [Epub ahead of print].

Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP et al. Expert Rev Hematol. 2014 Jan 29. [Epub ahead of print].

The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
McCarthy PL et al. Expert Rev Hematol. 2014 Jan 29. [Epub ahead of print].

Autologous stem cell transplantation for multiple myeloma in the era of novel agents.
Shimazaki C. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):14-5. doi: 10.1016/j.clml.2013.12.004. Epub 2013 Dec 21.

Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.
Wildes TM et al. J Natl Compr Canc Netw. 2014 Jan 1;12(1):128-36.

Overview of the international myeloma workshop 2013 kyoto.
Shimizu K. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):2-4. doi: 10.1016/j.clml.2013.12.007. Epub 2013 Dec 21.

Multiple myeloma maintenance therapy: A review of the pharmacologic treatment.
Shank BR et al. J Oncol Pharm Pract. 2014 Jan 6. [Epub ahead of print].

Bortezomib-based combination regimens in myeloma: more is not necessarily better.
Gonsalves WI et al. Leuk Lymphoma. 2014 Jan 28. [Epub ahead of print].

Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Zagouri F et al. Eur J Haematol. 2013 Dec 20. doi: 10.1111/ejh.12255. [Epub ahead of print].

Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review.
McShane CM et al. Cancer Epidemiol Biomarkers Prev. 2014 Jan 22. [Epub ahead of print].

Cooper K et al. Int J Technol Assess Health Care. 2014 Jan 22:1-8. [Epub ahead of print].

An overview of the progress in the treatment of multiple myeloma.
Kyle RA et al. Expert Rev Hematol. 2014 Jan 13. [Epub ahead of print].

Improved long-term survival in multiple myeloma up to the age of 80 years.
Kristinsson SY et al. Leukemia. 2014 Jan 14. doi: 10.1038/leu.2014.23. [Epub ahead of print].

Update on second primary malignancies in multiple myeloma: a focused review.
Landgren O et al. Leukemia. 2014 Jan 14. doi: 10.1038/leu.2014.22. [Epub ahead of print].

Multiple myeloma: genome sequencing, drug development and the future outlook.
Stewart AK et al. Expert Rev Hematol. 2014 Jan 9. [Epub ahead of print].

Getting to the root of the problem: the causes of relapse in multiple myeloma.
Chung KC et al. Expert Rev Anticancer Ther. 2014 Jan 8. [Epub ahead of print].

Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database.
Neal RD et al. Br J Cancer. 2013 Dec 24. doi: 10.1038/bjc.2013.791. [Epub ahead of print].

From ASH-multiple myeloma: Options for patients ineligible for stem-cell transplantation.
[No authors listed]. Nat Rev Clin Oncol. 2013 Dec 24. doi: 10.1038/nrclinonc.2013.240. [Epub ahead of print].